Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Cyclophosphamide 2Busulfan 2simtuzumab 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1ibrutinib 1SCIO-469 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Marrow Diseases × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡